Atali plant stabilization delays
Startup hiccups at Atali have impacted production plans; resolution expected by Q4 but may slip further, delaying revenue ramp-up.
AARTIPHARM / Q3-FY26 / risks
Keep the risk register visible.
Aarti Pharmalabs · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
API business margin pressure and degrowth
API revenue declined YoY due to pricing pressure and slower customer off-take; recovery may take several quarters.
CDMO revenue concentration on few molecules
80% of CDMO sales come from 7-8 projects; failure of any key project could materially impact revenue.
China rebate withdrawal benefit may not fully materialize
While China's rebate withdrawal could boost pricing, locked-in contracts may limit near-term realization.